Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
h5 vlp influenza vaccine + alhydrogel
- Development stage
- Unknown
- Lead developer
- Medicago
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a **combination vaccine formulation** consisting of a plant-derived **virus-like particle (VLP) vaccine presenting the hemagglutinin (HA) protein of the H5N1 influenza virus** and the **adjuvant alhydrogel** (aluminum hydroxide)[3][5][7]. The H5 VLP component is intended to elicit an immune response against H5N1 influenza, and the alhydrogel increases vaccine immunogenicity by promoting stronger antigen presentation and stimulating humoral (antibody-mediated) and cellular immune responses. It is primarily developed as a pandemic/pre-pandemic H5N1 avian influenza vaccine. Plant-derived VLP vaccines mimic the structure of the native virus but are non-infectious, and alhydrogel is a widely used adjuvant to enhance the immunogenicity of subunit and VLP vaccines[5][10].
- Other names
- h5 vlp vaccine + alhydrogelH5N1 VLP vaccine + alhydrogelplant-made H5 VLP vaccine + alhydrogel
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on h5 vlp influenza vaccine + alhydrogel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on h5 vlp influenza vaccine + alhydrogel.